

n	45
Age (mean (SD))	64.06 (12.80)
Gender: female (%)	35 (77.8)
Diagnosis n (%)	
IgG4-related Disease	2 (4.4)
Connective Tissue Disease	12 (26.7)
Rheumatoid Arthritis	24 (53.3)
Vasculitis	7 (15.6)
Peripheral B cells, absolute (median [IQR])	2.00 [0.00, 27.00]
Detectable B cells (%)	23 (51.1)
IgG (median [IQR]) mg/dL	761 [641, 988]
IgM (median [IQR]) mg/dL	48 [27, 65]
Months between RTX and Vaccination (mean (SD))	6.32 (5.22)
Days between Vaccine and Laboratory assessment (mean (SD))	16.40 (11.04)
Concomitant Medication n (%)	
Any csDMARD	25 (55.6)
Methotrexate	16 (35.6)
Mycophenolate Mofetil	3 (6.7)
Leflunomide	3 (6.7)
Hydroxychloroquine	3 (6.7)
Azathioprine	2 (4.4)
Sulfasalazine	1 (2.2)
Immunoglobulin therapy	2 (4.4)
Prednisone	12 (26.7)
Vaccine n (%)	
mRNA-1273	8 (17.8)
BNT162b2	37 (82.2)
Seroconversion n (%)	18 (40.0)
SARS Cov2-S Antibodies U/ml (median [IQR])	0.0 [0.0, 21.5]
Mean T cell response per SFCs/10 ⁶ PBMCs	157.37 (162.37)

Supplemental Table 2: Characteristics of patients with evaluated T cell-mediated immune response